

PREPRINT: Mechanisms of Motoric Cognitive Risk – hypotheses based on a systematic review and meta-analysis of longitudinal cohort studies of older adults

Donncha S. Mullin MBChB MRCPsych,^{1-4*} Alastair Cockburn MBChB,⁴ Miles Welstead MSc,⁵ Michelle Luciano PhD,⁵ Tom C. Russ PhD MRCPsych,¹⁻⁵ Graciela Muniz-Terrera PhD^{2,3}

^{1.} Alzheimer Scotland Dementia Research Centre, University of Edinburgh;

^{2.} Edinburgh Dementia Prevention Group, University of Edinburgh;

^{3.} Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh;

^{4.} NHS Lothian, Royal Edinburgh Hospital, Edinburgh;

^{5.} Lothian Birth Cohorts, Department of Psychology, University of Edinburgh.

* Dr Donncha S. Mullin, Division of Psychiatry, University of Edinburgh, Kennedy Tower, Royal Edinburgh Hospital, Morningside Terrace, Edinburgh, EH10 5HF, UK
Telephone: +44 (0)131 537 6000; Email: D.Mullin@ed.ac.uk

Manuscript statistics: Main text of 5000 words, abstract of 150 words, 4 figures, 3 tables, research in context 139 words, 52 references, 4 supplementary tables, 2 supplementary boxes.

Contributions: DSM, TCR and GMT generated the idea for the present manuscript. DSM conducted the literature search; screened the titles, abstracts, and full texts; extracted data and performed quality assessment; carried out the meta-analyses; drafted the manuscript; and is the guarantor. AC acted as independent second reviewer; independently extracted all the data and assessed the reporting quality of all full texts. MW assessed the search and screening process. All authors edited the manuscript and meet authorship criteria. No others meeting the criteria have been omitted.

Funding: The present manuscript received no direct funding. All funded researchers are independent of their funders with payments to institution. AC has no funding to declare. DSM is undertaking a PhD Clinical Research Fellowship funded by a one-off grant from the Masonic Charitable Foundation and the Royal College of Psychiatrists, United Kingdom. MW is funded by an Age UK [MR/M01311/1] grant for PhD studentship. ML is funded by a Biotechnology and Biological Sciences Research Council (BBSRC) project grant and is a previous recipient of the Moray Award for travel from University of Edinburgh. TCR is Principal Investigator 2021–2024 £1,518,000 grant, Chief Scientist Office: “NRS Neuroprogressive and Dementia Network” 2021–22 £216,666 grant, UKRI: “Sharing the diagnosis of dementia in the post-Covid clinic: patient and practitioner perspectives” 2019-21 £10,394 Catalytic grant, CSO: “Playlist for Life: Can personalised music be rapidly implemented in care homes as a non-pharmacological intervention for dementia?” 2017–18 £56,519 grant, NERC-MRC-CSO: “Modelling historical air pollution and dementia/cognitive decline – towards a life course approach” 2016-2021 £750,000 grant from Alzheimer Scotland for Phase 2 of the Alzheimer Scotland Dementia Research Centre Co-investigator 2019-2021 £733,246 Research grant, MRC: “Brain imaging and cognitive ageing in the Lothian Birth Cohort 1936: IV” 2017-18 \$40,000 from the Japan Agency for Medical Research and Development / New York Academy of Sciences Interstellar Initiative. TCR occasionally completes medicolegal reports for Solicitors in Edinburgh. These payments are

made to him but relate solely to his clinical work and not the academic work under review. TCR receives NHS study leave expenses (travel, accommodation, and registration). GMT is funded by the Medical Research Council methodology board and received consulting fees for an NIH-funded grant.

51
52
53

Declarations of interest: MW is vice-chair of the Scotland Research Ethics Committee. TCR has participated on the Alzheimer's Society and Alzheimer Scotland Advisory Boards - no payment. No other authors claim any disclosure.

57
58

Selected aspects of the present manuscript were presented in preliminary form as a poster at the 2021 Alzheimer's Association International Conference, online.

61

62 Abstract

63 We aimed to refine the hypothesis that Motoric Cognitive Risk (MCR), a syndrome combining
 64 measured slow gait speed and self-reported cognitive complaints, is prognostic of incident
 65 dementia and other major causes of morbidity in older age. We propose mechanisms on the
 66 relationship between motor and cognitive function and describe a roadmap to validate these
 67 hypotheses. We systematically searched major electronic databases from inception to August
 68 2021 for original longitudinal cohort studies of adults aged ≥ 60 years that compared an MCR
 69 group to a non-MCR group with any health outcome. Fifteen cohorts were combined by meta-
 70 analysis. Participants with MCR were at an increased risk of cognitive impairment (adjusted
 71 hazard ratio [aHR] 1.76, 95%CI 1.49-2.08; $I^2=24.9\%$), dementia (aHR 2.12, 1.85-2.42; 33.1%),
 72 falls (adjusted Relative Risk 1.38, 1.15-1.66; 62.1%), and mortality (aHR 1.49, 1.16-1.91; 79.2%).
 73 The prognostic value of MCR is considerable and mechanisms underlying the syndrome are
 74 proposed.

75

76 **Keywords:** Motoric cognitive risk, gait, dementia, review, meta-analysis, mechanism,
 77 pathophysiology, falls, mortality, subjective cognitive complaint, prognostic, prevention

78 **Systematic review registration:** PROSPERO CRD42020225183.

79

1. Narrative

1.1 Central question

Can a gait-based syndrome, Motoric Cognitive Risk (MCR), predict dementia and other age-related negative health outcomes? If so, what are the possible underlying mechanisms?

1.2 Objective

This paper is a proposal for an update of the Hypothesis on the Motoric-cognitive Mechanism in Neurodegeneration-Dementia-Alzheimer¹ syndrome (abbreviated hereafter as the Hypothesis) based on a thorough systematic review and meta-analysis of the evidence. The present work intends to: (1) promote new thinking about the prognostic value of MCR in dementia and other major causes of morbidity in older age; and (2) propose shared mechanisms between MCR and neurodegeneration and outline a roadmap for further work to validate these hypotheses. This report aims to synthesize and critique current evidence on MCR and describe challenges to the MCR concept and the use of MCR as a clinical tool.

1.3 Current knowledge

As there are still no effective treatments for dementia, any biomarker that supports early identification of high-risk individuals would allow time for lifestyle modification, planning for future care needs, and could ultimately contribute to a reduction in overall prevalence of dementia. Slow gait speed and self-reported cognitive complaints show potential to be such biomarkers as they are some of the earliest reported precursors in the pre-clinical stage of dementia, occurring 10-15 years before dementia diagnosis.^{1,2} Motoric cognitive risk (MCR) syndrome is a high-risk state combining objective (measured) slow walking speed and subjective (self-reported) cognitive complaint in those able to ambulate and in the absence of dementia.³

First defined by Verghese in 2013⁴, MCR has incremental predictive ability over either slow gait or cognitive complaint alone.⁵ Gait is a complex task requiring coordination between widespread brain regions, therefore MCR may reflect neurodegeneration occurring in the preclinical stage of dementia. Imaging studies in the MCR field indicate atrophy of executive function areas (frontal and pre-frontal lobe networks).⁶

The only existing meta-analysis of MCR⁷ found that MCR predicts cognitive impairment and dementia. However, this meta-analysis had significant methodological limitations, including pooling the results of different effect measures (e.g., hazard ratios and odds ratios) and, focusing on the term “MCR”, thus only including studies published from 2013 onward and excluding earlier papers examining the same construct without naming it as such. We address these limitations in our study. Other studies report that MCR identifies those at risk of falls,^{8–10} post-falls hip fractures,⁹ disability,¹¹ and mortality,^{12,13} but these studies have not yet been pooled in a meta-analysis. Other non-systematic MCR reviews focused on risk factors for developing MCR¹⁴ or aimed to give a more general overview of the MCR construct.⁶

1.4 Knowledge gap and importance of this study

Important conditions such as dementia or falls are projected to affect such a large number of people over the next 30 years that even small reductions in the incidence – or delaying the age of onset which would have the same result – are likely to have significant effects on numbers of people affected and consequently the huge associated public health costs.^{5,14} Could there be shared mechanisms explaining the association of MCR with both these outcomes? If so, identifying and targeting these mechanisms could reduce the prevalence of these major causes of morbidity and mortality in older adults. Furthermore, if a quick, inexpensive, and easy-to-measure clinical construct could reliably identify people at high risk of developing either or both

dementia and falls, along with other adverse health outcomes such as cognitive impairment and mortality, it would be an important public health tool and would be equally implementable in low-to-middle income countries. Our study addresses this knowledge gap and proposes hypotheses on the underlying mechanisms.

1.5 Limitations

We were unable to obtain raw data from every eligible study to allow for calculation of a comparable summary effect measure for each study for inclusion in the meta-analysis – an individual participant meta-analysis. Therefore, some studies had to be left out of the pooled result, reducing the overall power. We believe this important compromise ensures our findings are as valid and reliable as possible based on the published literature while avoiding potential significant delays to undertaking this novel work. Most studies in our review had a degree of risk of bias (ROB) due to how they managed missing data and confounding factors, and a lack of generalizability (section 2.1.6). These are common limitations in cohort studies and partly explain why they are lower down the hierarchy of evidence compared to randomized controlled trials. We accounted for substantial heterogeneity in the mortality outcome by downgrading our Grading of Recommendations Assessment, Development and Evaluation (GRADE) certainty assessment for inconsistency (see section 2.2.5). Although some might avoid pooling our mortality data due to statistical heterogeneity, we believe the summary data provide an important global perspective on MCR.¹³ There is a relatively small number of studies for each health outcome in the meta-analysis, meaning that statistical tests for publication bias lacked power to detect real asymmetry from chance, although visual inspection of funnel plots is reassuring (section 2.3.5). Finally, dementia is a clinical diagnosis, but in the studies included it was often determined using surrogate markers such as scores in cognitive tests, increasing heterogeneity and decreasing the generalizability of our findings. This is a common issue in dementia research

using cohort data. Reassuringly, the results of studies that diagnosed dementia using clinical criteria^{4,5} were consistent with those using surrogate markers.^{11,15}

1.6 Discussion

Our results for risk of cognitive impairment and dementia in participants with MCR at baseline were consistent with the only existing meta-analysis on the topic.⁷ This earlier meta-analysis reported that individuals with MCR were at a 70% increased risk of developing cognitive impairment (adjusted Hazard Ratio [aHR] 1.70, 95%CI 1.46-1.98) and a 150% increased risk of developing dementia (aHR 2.50, 95%CI 1.75-2.39). The slight differences reflect our inclusion of new studies and two major strengths of our study, namely our decisions to only pool summary effect measures of the same type and to always use the most adjusted effect measure reported. Accordingly, our findings have reduced confounding and are likely to be more conservative. Furthermore, by focusing on the term “MCR”, the previous meta-analysis only included studies published from 2013 onward, unlike our search which captured any study combining slow gait and subjective cognitive complaint since database inception.

Our paper makes methodological advances on the existing meta-analysis with regards to cognitive impairment and dementia outcomes,⁷ and it is the first to meta-analyze MCR studies reporting on falls and mortality outcomes. As MCR is a recently defined construct, more research is needed to increase certainty in each of our findings, particularly falls prediction. Other outcomes more likely in those with MCR at baseline include recurrent falls, post-falls hip fractures, and disability, but these outcomes require further research to allow for robust meta-analysis.

1.6.1 Hypotheses on mechanisms underlying MCR

Interactions between MCR, poor brain health, falls, and increased mortality are likely due to a range of biological, psychological, and social mechanisms. Causality is likely to be bidirectional, and the mechanisms may be multifactorial. There is unlikely to be one, unifying mechanism linking MCR with these negative health outcomes, but, based on recent evidence, we propose hypotheses to explain some of the potential underlying biological mechanisms.

Epidemiological and clinical

MCR prevalence increases with age with rates of 8.9% in the 60-74 years group and 10.6% in the ≥ 75 years group⁵. MCR may increase the risk of dementia, falls and mortality by contributing to geriatric syndromes such as delirium, depression, and medication mismanagement. Lower education is associated with increased risk of MCR^{5,13,16} and is an established risk factor for dementia. Low physical activity is another lifestyle risk factor shared by MCR with dementia, falls, disability, and increased mortality.^{11,13,17} Reduced concentration and psychomotor retardation are well-recognized symptoms of depression, so it is no surprise that depression has been associated with MCR.¹⁸ Personality traits such as neuroticism¹⁹ have also been associated with MCR, which may in part be due to an increased likelihood in this population to report subjective cognitive complaint. Pilot trials to improve executive function by cognitive training, dual-task ‘walking while talking’, or brain stimulation have improved gait speed.⁶

Neuropathology

Emerging data suggest that both neurodegenerative and vascular changes may contribute to progression to dementia in those with MCR.²⁰ It is widely accepted that cerebral small vessel disease (SVD) is an important cause of dementia and it is estimated that over one third of dementias could be prevented by preventing stroke.²¹ Lacunar infarcts in the frontal lobe were associated with MCR even after adjusting for vascular risk factors and presence of white matter

hyperintensities (adjusted Odds Ratio (aOR): 4.67, 95% CI: 1.69-12.94).²² SVD is also a significant contributor to risk of falling and SVD, especially in the frontal lobes, and has been linked to increased mortality.¹² However, adults free of dementia with slow gait had associated amyloid β brain deposition, independent of underlying vascular change.²³

Cognition and gait share many other risk factors such as cardiovascular disease and diabetes mellitus²⁴ so it is no surprise that a pooled meta-analysis found that MCR was associated with both of these chronic conditions, as well as hypertension and stroke.²⁵ These findings support our hypothesis that a vascular mechanism may underlie the pathophysiology of MCR syndrome.

Neuroimaging and neurophysiology

A 2019 review reported that MCR was associated with lower gray matter volume in the premotor and prefrontal cortices, but had no significant association with white matter abnormalities.⁷ The authors concluded that the pathophysiology of MCR was more likely due to neurodegenerative rather than ischemic lesions.⁷ This conclusion was admittedly based on a small number of imaging studies and it was hypothesized that MCR detects individuals at such an early stage of the disease process leading to dementia that the consequences of the vascular component may not yet be detected.⁷ Furthermore, MCR was associated with frontal lacunar infarcts in a study of 139 older adults in India.²²

Genetics

The first study to investigate individual-level genetic burden in relation to a predementia syndrome examined the polygenic inheritance of MCR in a sample of 4,915 older individuals.²⁶ The authors examined nine phenotypes associated with MCR and found that obesity-related genetic traits increase the risk of MCR syndrome. Obesity in older adults is an established risk factor in falls, disability and increased mortality.^{27,28}

230

231 A prospective examination of inflammatory cytokine genes found that polymorphisms which
 232 lead to over-expression of the anti-inflammatory cytokine Interleukin-10 (IL-10) are associated
 233 with increased MCR incidence.²⁹ While this makes any shared neuroinflammatory pathway
 234 between MCR and dementia less probable, an over-expression of IL-10 points toward a
 235 proamyloidogenic hypothesis of cognitive decline.²⁹ Early work in mice models found that IL-10
 236 expression leads to increased amyloid β accumulation and reduction in synaptic proteins as well
 237 as increasing expression of *APOE* and suppressed phagocytosis of β -amyloid by microglia.³⁰ This
 238 link between *APOE* and MCR is perhaps unsurprising as the *APOE* ϵ 4 allele was independently
 239 associated with increased risk of gait speed decline and disability in older men.³¹

240

241 **Cellular mechanisms**

242 No specific mechanistic work on MCR at the cellular level has been performed to date.
 243 However, emerging evidence on the effects of Alzheimer's disease pathology on motor neuron
 244 function in transgenic mice merit consideration. For example, many studies have reported on the
 245 impaired motor performance such as beam walking and significant motor neuron axonopathy in
 246 transgenic mice with β -amyloid mutations.^{1,32} It will be fascinating to assess if future studies
 247 treating developed or preventing Alzheimer's disease pathologies improves or prevents further
 248 declines of motor function.¹

249

250 **1.7 Major challenges for the Hypothesis**

251 First, the definition of MCR requires standardization to allow for better comparison of MCR
 252 prevalence rates and prognostic value across populations. The range of methods for diagnosing
 253 subjective cognitive complaint highlights the need for a consistent definition of MCR in future
 254 studies.

255

256 Early work by Verghese et al.⁴ found that MCR was better at predicting vascular dementia than
 257 Alzheimer dementia, but more recent work in an independent cohort¹⁵ found conversely that
 258 MCR was better at predicting Alzheimer's dementia than non-Alzheimer's dementia. This
 259 challenges the premise that early upstream vascular alterations degrade the brain structures
 260 shared by cognitive and motor function systems, namely frontal and prefrontal motor cortex.^{20,21}

261

262 **1.8 Conclusions and next steps**

263 The motoric-cognitive hypothesis of neurodegeneration does not seem to have one unifying
 264 underlying mechanism, so future steps to elucidate these will require a multidisciplinary approach
 265 exploring the issue using complementary techniques.

266

267 1. The relative contributions from cortical motor regions to neuropsychological tests that
 268 comprise part of the clinical diagnosis of dementia remain to be addressed.¹

269

270 2. Longitudinal studies of at-risk populations with genetic, neurophysiological,
 271 neuroimaging, or other biomarkers and pathological validation will help determine the
 272 progress of motor and cognitive impairment in dementia.³³

273

274 3. A large-scale discovery genome-wide association study of MCR is an important step to
 275 identify underlying biological mechanisms of MCR. This would identify targets for
 276 further investigation and possibly treatment to reduce MCR and ultimately dementia,
 277 falls, disability, and excess mortality. The generation of a reliable MCR polygenic risk
 278 score might have clinical utility for early prediction, and thus prevention, of those at risk
 279 of MCR.

280

281 4. Interventional trials are important to assess whether targeting slow gait and subjective
282 cognitive impairment delays or reverses MCR, and whether this reduces transition to
283 cognitive impairment, dementia, falls, and excess mortality.

284

285 **2. Consolidated Results and Study Design**

286 **2.1 Methodology**

287 This systematic review was conducted following the updated guidelines of Preferred Reporting
288 Items for Systematic reviews and Meta-Analyses (PRISMA 2020)³⁴ and the meta-analysis
289 followed the Meta-Analyses of Observational Studies in Epidemiology (MOOSE) guidelines.³⁵
290 The protocol was pre-registered in the international prospective register of systematic reviews
291 (PROSPERO CRD42020225183).

292

293 **2.1.1 Search strategy**

294 We searched the AMED, APA PsychInfo, CINAHL, Cochrane, EMBASE and Ovid
295 MEDLINE databases from conception to 20/08/2021, then carried out a backwards and
296 forwards citation search with no language or publication date restrictions. The search strategy
297 was devised iteratively with support from an academic librarian, and the strategy was peer
298 reviewed using the Peer Review of Electronic Search Strategies (PRESS) checklist.³⁶ The full
299 search strategy is in supplementary table 1.

300

2.1.2 Eligibility criteria

We used the PICOT (Population; Intervention; Comparator; Outcome; Timing/Type) system to design our review question (supplementary box 1).³⁷ In summary, we examined longitudinal cohort studies of community-based adults aged ≥ 60 years with an MCR group compared to a non-MCR group for any health outcome with a minimum of one year follow-up. Only peer-reviewed full-text articles were included in the meta-analysis and synthesis.

2.1.3 Screening and selection

Two authors (DM and AC) independently reviewed all titles then all included abstracts using Covidence software.³⁸ If the study appeared to meet the selection criteria, the same two investigators independently reviewed the full text. Discrepancies were resolved through open discussion and verified by a third author when necessary.

2.1.4 Data collection process

We iteratively designed a bespoke data extraction tool based on the CHARMS-PF (CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies, adapted for prognostic factors) template³⁷, which two authors (DM and AC) used independently to extract data from eligible studies (supplementary table 2). We then compared the extracted data and resolved any discrepancies through discussion and referring to the study in question. The combined data extraction tool was then double-checked for accuracy. Whenever study details were unclear, we contacted study authors for further information.

2.1.5 Data items

We extracted the following data for the exposure variable (MCR): slow gait measurement protocol, average gait speed, subjective cognitive complaint measurement method and MCR prevalence rate. For our outcome variables, we recorded method of measurement as well as the most adjusted model results of any health outcome result, whether reported as adjusted hazard ratio (aHR), adjusted odds ratio (aOR), or adjusted relative risk (aRR), and their corresponding 95% confidence intervals (CI) and p-values, if available. Unadjusted model results were not reported frequently enough to allow meaningful comparison on synthesis. To inform assessment of residual confounding, we recorded the covariates adjusted for in each model. Where an outcome was reported over various follow-up timepoints we selected those timepoints most common across studies to minimize meta-analysis heterogeneity. Other data items extracted included, author name, year, country, cohort, size, the study design, and participant characteristics.

2.1.6 Study quality and risk of bias assessment

We performed a ROB assessment, using an expanded version of the Quality In Prognosis Studies (QUIPS) tool recommended by the Cochrane Prognosis Methods Group to assess ROB in prognostic factor studies.³⁷ We generated a summary ROB plot illustrating the overall ROB of the literature base, and a ROB traffic light plot to illustrate the ROB of each study. The ROB assessments were incorporated into our meta-analysis at the grading of evidence stage.

2.2 Meta-analysis

2.2.1 Eligibility for each synthesis

We tabulated the study outcome characteristics and compared each against our planned outcome to ensure that the study outcome was valid. We only included in the meta-analysis those studies with outcomes which were judged satisfactory by our clinical content experts. Only health outcomes reported from at least three cohorts were included in the meta-analysis, to ensure appropriate synthesis.

2.2.2 Effect measures

We used aHR and 95% CI to synthesize studies reporting cognitive impairment, dementia, and mortality outcomes, and aRR and 95% CIs to synthesize studies reporting falls as the outcome. These were the effect measures most reported in eligible studies for each of these outcomes, thus allowing inclusion of most studies. When a study reported the effect measure in a way incompatible with our analysis, we contacted the authors to request data to allow for our own calculation (e.g., aHR) or we converted the effect measure (e.g., aOR to aRR), if possible and appropriate, based on methods suggested by Tierney.³⁹ If these attempts were not successful, we omitted the study from our meta-analysis to avoid comparing different effect measures in the one analysis. In all cases, only the most adjusted effect measures were used.

2.2.3 Synthesis methods

We log-transformed our effect measures and their 95% CIs to make them normally distributed, an assumption of our meta-analysis model. We then calculated log standard error using the methods described in the Cochrane Handbook v6.2.⁴⁰

We used a random-effect model (REM) to allow for within-study sampling error and between-studies variability due to varying study characteristics. The relative lack of small studies supported our decision to use the REM approach (as smaller studies receive larger weights in REM in comparison to fixed-effect modelling). The degree of heterogeneity was calculated using a restricted maximum-likelihood estimator, following recent guidance.⁴⁰ The extent and impact of between-study heterogeneity were visually displayed in forest plots and reported as the tau-squared and I-squared statistic, accompanied by 95% CIs to judge our confidence about these metrics. I-squared was chosen over Cochrane's Q to better account for the small number of studies in each analysis. Prediction intervals are included in the forest plots to illustrate the range for which we can expect the effects of future studies to fall, based on our present evidence in the meta-analysis. Prediction intervals help overcome any limitations of the I-squared and tau-squared methods.⁴¹ Meta-analysis was performed by one author in R (version 4.0.2) using the metafor (2.4.0) and dmetar (0.0.9) packages.⁴²

We tabulated our study characteristics structured by outcome domain, ordered from low to high ROB to orientate readers to the most robust evidence (table 1). The results of the meta-analyses are displayed in forest plots for each outcome, displaying the effect estimates and confidence intervals of each study and the summary estimate. The plots are ordered by study weight to highlight any patterns in the data.

2.2.4 Assessing publication bias or outcome reporting bias

We produced funnel plots for meta-analysis of MCR for each health outcome to allow for visual assessment of small-study effects. These were assessed for asymmetry using Egger's test. To assess outcome reporting bias, two reviewers independently compared the outcomes reported in the methods and results sections of the studies.

2.2.5 Certainty assessment methods

Our default starting position regarding certainty in the level of evidence was in keeping with the Cochrane guidance to generally regard evidence from sound observational studies as low quality.⁴⁰ We modified the GRADE considerations adapted for prognosis research as recommended by Huguet⁴³ to assess the certainty of the body of evidence as it related to the studies included in the meta-analyses for each outcome. See section 3.1 and supplementary box 2 for full details.

2.3 Results

2.3.1 Study selection

We found 705 records on database searching, following de-duplication. We sought retrieval of full-text reports for 94. We included 15 studies from the databases search,^{4,5,8-13,15-17,44-47} with 11 of these proving eligible for meta-analysis. We then performed backwards and forwards citation searching by reviewing the reference list of these studies, as well as those of three reviews^{7,14,48} and one editorial paper³³ on MCR. Of the 1800 records found this way, we reviewed full-text reports for 35 but included no additional papers. One longitudinal study which appeared to meet inclusion criteria was excluded as the MCR group defined using slow gait speed as a criteria was not followed up longitudinally.³ Figure 1 shows the PRISMA flow diagram of study selection.

2.3.2 Study characteristics

Error! Reference source not found. shows the key characteristics for each cohort included in the meta-analysis, structured by outcome, and ordered by ROB from low to high risk. More detail is available in supplementary table 3. All studies were published from 2013 onwards. Six cohorts were based in the USA, three from European countries, and one from each of Canada, Japan, China, Mexico, Australia, and New Zealand. Cohort sizes ranged from 176 to 6795

participants (average 2036). All participants were older adults at baseline with a mean age ranging from 65 to 84.6 years (average 76 years). Gait speed was assessed using a stopwatch in most studies other than the three which reported on cohorts that used a computerized walkway.^{4,5,8} The measuring distance ranged from 2.4 to 6 meters and most cohorts measured usual walking speed, although two studies measured maximum walking speed.^{10,46} Slow gait was defined as one standard deviation or more below age- and sex-matched means in the population in all but two cohorts, one of which classed as slow walkers all those walking <0.8 meters per second (or <0.66 meters per second if female less than 1.45m in height)¹⁶ and the other which classed as slow walkers all those in the lowest 20th percentile of the cohort population.⁴⁷ Subjective cognitive complaint was measured using different methods in different cohorts, such as the memory item from the 15-item Geriatric Depression Scale,^{8,10,11,15,17,44,46} the eight-item informant interview (AD8),¹⁷ the Clinical Dementia Rating scale,¹⁷ the 15-item Consortium to Establish a Registry for Alzheimer's Disease (CERAD) questionnaire.⁴ Of note, studies on the EPIDOS cohort included in this review and meta-analysis used an objective measure of cognitive complaint, namely any incorrect responses on the Short Portable Mental Status Questionnaire (SPMSQ). Accordingly, results should be treated with caution.^{9,13,15} In other studies, a positive response from participants to a question such as "Is your memory worse than 10 years ago?" was sufficient.¹²

2.3.3 Results of ROB assessments

Figure 2 contains a summary ROB of the pooled studies (top) as well as a traffic-light plot (bottom) showing the ROB of the individual studies, assessed against the nine domains. In the pooled summary, the domains with highest ROB were due to missing data, exposure variable measurement, confounding and generalizability. In the traffic-light plot, there was a high ROB in at least one domain in the majority (7/11) of studies, and all studies contained at least one

domain judged as being of some concern. Overall, six studies had low ROB, four studies had some concerns, and one study had a high ROB.

2.3.4 Meta-analysis of health outcomes predicted by MCR

The meta-analysis findings are summarized in the forest plots and described in more detail below (figure 3).

Dementia

We combined six cohorts from four studies that examined dementia as an outcome, totaling 9,955 participants.^{4,5,11,45} Four cohorts were from two studies with a low ROB^{4,5} and two were from studies with a moderate risk of overall bias.^{11,45} Individuals with MCR at baseline were over twice as likely to develop dementia compared to those without MCR, over an average follow-up of 4.3 years (aHR 2.12, 95%CI 1.85-2.42, $p < 0.0001$, $I^2 = 33.1\%$, $\tau^2 = < 0.0001$, prediction interval 1.75-2.56).

Cognitive Impairment

Six cohorts from three studies, including a total of 6,458 participants, reported on cognitive impairment as an outcome. Five cohorts were from two studies with a low risk of overall bias^{5,16} and one⁴⁷ with a moderate risk of overall bias. Those with MCR at baseline were at an increased risk of developing cognitive impairment compared to those without MCR, over an average follow-up of 5.6 years (aHR 1.76, 95%CI 1.49-2.08, $p < 0.0001$, $I^2 = 24.9\%$, $\tau^2 = 0.0095$, prediction interval 1.23-2.52).

Falls

We combined eight cohorts from three studies, including a total of 12,640 participants with falls as an outcome. Two cohorts were from one study with a high risk of overall bias, mainly due to this study's small sample size and method of dealing with confounders.¹⁰ These cohorts were weighted in the meta-analysis in accordance with their results imprecision, so their effect on the overall result was minimal (combined weighting of 6.3%). One cohort was from a study with a moderate ROB,⁹ while the other five cohorts were from a study with a low ROB.⁸ Those with MCR at baseline were at a 38% relative risk increase of falls compared to those without MCR (aRR 1.38, 95%CI 1.15-1.66, $p=0.0005$, $I^2=62.1\%$, $\tau^2=0.039$, prediction interval 0.91-2.36). The average follow-up of all cohorts was 1.4 years. A subgroup analysis excluding the two cohorts with a high risk of overall bias (total $n=478$ participants) made no difference to the effect measure of prognostic ability for MCR at baseline with falls on follow-up (aRR 1.38, 95%CI 1.14-1.69, $p=0.0013$, $I^2=70.2\%$, $\tau^2=0.043$, prediction interval 0.73-2.63).

Mortality

Four cohorts from two studies, including 19,818 participants, reported on mortality as an outcome. Three of these came from a study with a low risk of overall bias,¹² with the other study¹³ having a moderate risk of overall bias. Those with MCR at baseline were at an increased risk of mortality compared to those without MCR, over an average follow-up of 5.3 years (aHR 1.49, 95%CI 1.16-1.91, $p<0.0001$, $I^2=79.2\%$, $\tau^2=0.0477$, prediction interval 0.50-4.42).

2.3.5 Bias of studies or outcomes included in the meta-analysis

On visual inspection of the funnel plots, both the dementia and cognitive impairment outcomes appear to be missing smaller studies with a smaller effect size (figure 4). As there are fewer than ten studies for each outcome, any test for funnel plot asymmetry will have low power for

distinguishing chance from real asymmetry.⁴⁰ Nonetheless, the results from Egger's test did not support asymmetry for dementia ($p=0.15$), cognitive impairment ($p=0.06$), falls ($p=0.69$) or mortality ($p=0.54$).

There was no evidence of selective non-reporting of results from any of the studies included in this review or meta-analysis.

3. Further detail on methods and results

3.1 Further methodological details

3.1.2 Quality assessment of included studies

Prior to ROB assessment, two authors (DM and AC) independently evaluated the methodological quality of the selected studies using a customized quality assessment tool that builds on the 14 criteria of the Cochrane recommended National Institute for Health (NIH) Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies.⁴⁹ An additional 15 criteria from the Strengthening The Reporting of Observational Studies in Epidemiology (STROBE) guidelines⁵⁰ were added to our tool, resulting in a total of 29 criteria by which each study was assessed (supplementary table 4). Two authors independently rated each study quality overall as “high” if most criteria were met and there was little risk of bias (ROB), “satisfactory” if most criteria were met with some flaws in the study, or “low” when most criteria were not met, and/or there were significant flaws relating to key aspects of study design. Any discrepancies in judgements were resolved by discussion to reach a consensus. There were no discrepancies in our independent overall impression of each study. Our approach fits with that recommended by the Cochrane Handbook v6.2.⁴⁰

In addition to this detailed quality assessment, we performed a more succinct ROB assessment as described in section 1.5.5. From the criteria in our quality assessment tool, we selected those most relevant to ROB: (i) bias due to lack of study focus; (ii) bias arising from cohort used; (iii) bias due to MCR measurement; (iv) bias due to outcome measurement; (v) bias due to missing data; (vi) bias due to confounding; (vii) bias due to follow-up; (viii) bias due to results precision; (ix) bias due to lack of generalizability. These criteria are more appropriate when assessing ROB of studies describing a syndrome such as MCR than the recently developed Prediction model Risk Of Bias ASsessment Tool (PROBAST) tool,⁵¹ which assesses multivariable prediction models. The risk of bias plots were created in the coding language R using the “robvis (0.3.0.9)” package.⁵² The code syntax is openly available on GitHub (<https://github.com/d-mullin?tab=repositories>).

3.1.2 Assessment of certainty in the body of evidence

We assessed the certainty of the body of evidence for MCR as a predictor of each outcome in the meta-analysis against the GRADE considerations adapted for prognosis research as recommended by Huguët⁴³, see section 1.6.5. We graded the certainty in the results for MCR as a predictor of dementia, cognitive impairment, falls, and mortality as low (see table 2). This low certainty is typical for prognosis research using even sound observational studies.⁴⁰ The seven GRADE criteria considered, and our impressions for each, are described in supplementary box 2 of the appendix.

3.2 Further results

3.2.1 Studies excluded from meta-analysis

A further two eligible studies^{15,46} reported on MCR as a predictor of dementia and two more as a predictor of cognitive impairment^{17,44} but, due to how the effect size was reported in each, (e.g.,

reporting OR rather than HR) we were unable to include them in our meta-analysis. Despite correspondence with study authors, we did not obtain the data necessary to allow calculation of the effect measure used in our meta-analysis. Reassuringly, these excluded studies share similar characteristics and direction of effect size to those included in the meta-analysis (table 3). They were judged as having either a moderate or high ROB. The effect precision was poor in three of the studies and not reported in the other, so if it had been possible to include these in the meta-analysis, they would have had a relatively small weighting and therefore, a minimal impact on the overall result.

MCR at baseline was reported to predict other health outcomes on follow-up, but there were not enough different cohorts reporting on the same outcomes to allow for meta-analysis. One study found that MCR was a predictor of incident disability after 2.5 years (aHR 2.25 (1.39-3.67) $p=0.001$).¹¹ Disability was defined as a primary care doctor evaluated need for new long-term care insurance certification. Another study, already included in our meta-analysis for falls at one year, also reported on MCR as a predictor of recurrent falls, defined as two or more falls, (aHR 1.46 (1.04-2.05) $p=0.030$) and of post-falls hip fractures (aHR 2.54 (1.78-3.63) $p\leq 0.001$).⁹

Research in Context

Systematic review: We systematically retrieved and reviewed the literature using traditional sources and correspondence with authors. While the predictive value of MCR for cognitive impairment, dementia, falls, and mortality have been reported in sufficient cohorts to allow for meta-analysis, other outcomes such as disability were not, so were reported in narrative form.

Interpretation: Our findings led to an integrated hypothesis describing the pathophysiology of MCR. This hypothesis is consistent with epidemiological, imaging, and genetic findings currently in the public domain.

Future directions: This manuscript proposes a framework for the generation of new hypotheses and describes a roadmap to validate these hypotheses. Examples include: (a) clarifying the definition of subjective cognitive complaint; (b) longitudinal studies with biomarkers and pathological analysis; (c) genome wide association studies of MCR to identify genetic polymorphisms and potential treatment targets of interest.

Correspondence

Dr Donncha S. Mullin, Division of Psychiatry, University of Edinburgh, Kennedy Tower, Royal Edinburgh Hospital, Morningside Terrace, Edinburgh, EH10 5HF, UK
Telephone: +44 (0)131 537 6000; Email: D.Mullin@ed.ac.uk

Acknowledgements

Ruth Jenkins, academic support librarian at the University of Edinburgh, helped with search terms and recommending databases. Dr Sue Lord, Lecturer at the Auckland University of Technology, New Zealand, supplied raw data from her study to allow for calculation of appropriate effect measure.

REFERENCES

1. Albers MW, Gilmore GC, Kaye J, et al. At the interface of sensory and motor dysfunctions and Alzheimer's disease. *Alzheimer's Dement.* 2015;11(1):70-98. doi:10.1016/J.JALZ.2014.04.514
2. Verghese J, Wang C, Lipton RB, Holtzer R, Xue X. Quantitative gait dysfunction and risk of cognitive decline and dementia. *J Neurol Neurosurg Psychiatry.* 2007;78(9):929-935. doi:10.1136/jnnp.2006.106914
3. Ayers E, Verghese J. Gait Dysfunction in Motoric Cognitive Risk Syndrome. Montero-Odasso M, Perry G, eds. *J Alzheimer's Dis.* 2019;71(s1):S95-S103. doi:10.3233/JAD-181227
4. Verghese J, Wang C, Lipton RB, Holtzer R. Motoric cognitive risk syndrome and the risk of dementia. *Journals Gerontol - Ser A Biol Sci Med Sci.* 2013;68(4):412-418. doi:10.1093/gerona/gls191
5. Verghese J, Annweiler C, Ayers E, et al. Motoric cognitive risk syndrome: Multicountry prevalence and dementia risk. *Neurology.* 2014;83(8):718-726. doi:10.1212/WNL.0000000000000717
6. Meiner Z, Ayers E, Verghese J. Motoric cognitive risk syndrome: A risk factor for cognitive impairment and dementia in different populations. *Ann Geriatr Med Res.* 2020;24(1):3-14. doi:10.4235/agmr.20.0001
7. Sekhon H, Allali G, Launay CP, et al. Motoric cognitive risk syndrome, incident cognitive impairment and morphological brain abnormalities: Systematic review and meta-analysis. *Maturitas.* 2019;123(February):45-54. doi:10.1016/j.maturitas.2019.02.006
8. Callisaya ML, Ayers E, Barzilai N, et al. Motoric Cognitive Risk Syndrome and Falls Risk: A Multi-Center Study. Montero-Odasso M, ed. *J Alzheimer's Dis.* 2016;53(3):1043-1052. doi:10.3233/JAD-160230
9. Beauchet O, Sekhon H, Schott A-MM, et al. Motoric Cognitive Risk Syndrome and Risk for Falls, Their Recurrence, and Postfall Fractures: Results From a Prospective Observational Population-Based Cohort Study. *J Am Med Dir Assoc.* 2019;20(10):1268-1273. doi:10.1016/j.jamda.2019.04.021
10. Lord S, Moyes S, Teh R, et al. Gait, cognition and falls over 5 years, and motoric cognitive risk in New Zealand octogenarians: Te Puāwaitanga o Nga Tapuwae Kia Ora Tonu, LiLACS NZ. *BMC Geriatr.* 2020;20(1):1-8. doi:10.1186/s12877-020-1420-8
11. Doi T, Shimada H, Makizako H, et al. Motoric Cognitive Risk Syndrome: Association with Incident Dementia and Disability. *J Alzheimer's Dis.* 2017;59(1):77-84. doi:10.3233/JAD-170195
12. Ayers E, Verghese J. Motoric cognitive risk syndrome and risk of mortality in older adults. *Alzheimer's Dement.* 2016;12(5):556-564. doi:10.1016/j.jalz.2015.08.167
13. Beauchet O, Sekhon H, Launay CP, et al. Motoric cognitive risk syndrome and mortality: results from the EPIDOS cohort. *Eur J Neurol.* 2019;26(5):794-e56. doi:10.1111/ene.13891
14. Semba RD, Tian Q, Carlson MC, Xue Q-LL, Ferrucci L. Motoric cognitive risk syndrome: Integration of two early harbingers of dementia in older adults. *Ageing Res Rev.* 2020;58(January):101022. doi:10.1016/j.arr.2020.101022
15. Beauchet O, Sekhon H, Launay CP, Rolland Y, Schott AM, Allali G. Motoric cognitive risk syndrome and incident dementia: results from a population-based prospective and observational cohort study. *Eur J Neurol.* 2020;27(3):468-474. doi:10.1111/ene.14093
16. Aguilar-Navarro SG, Mimenza-Alvarado AJ, Aguilar-Esquivel JE, Yeverino-Castro SG, Juarez-Cedillo T. Motoric Cognitive Risk Syndrome: Prevalence and Risk of Cognitive Impairment in a Population Studied in the Mexican Health and Aging Study 2012–2015. *J Nutr Heal Aging.* 2019;23(3):227-231. doi:10.1007/s12603-019-1160-7

- 635 17. Allali G, Ayers EI, Verghese J. Motoric Cognitive Risk Syndrome Subtypes and Cognitive
636 Profiles. *Journals Gerontol - Ser A Biol Sci Med Sci*. 2016;71(3):378-384.
637 doi:10.1093/gerona/glv092
- 638 18. Sekhon H, Allali G, Beauchet O. The association of anxio-depressive disorders and
639 depression with motoric cognitive risk syndrome: results from the baseline assessment of
640 the Canadian longitudinal study on aging. *GeroScience*. 2019;41(4):409-418.
641 doi:10.1007/s11357-019-00093-z
- 642 19. Stephan Y, Sutin AR, Canada B, Terracciano A. Personality and Motoric Cognitive Risk
643 Syndrome. *J Am Geriatr Soc*. 2020;68(4):803-808. doi:10.1111/jgs.16282
- 644 20. Khachaturian ZS, Kuller LH, Khachaturian AS. Strategic goals and roadmap for dementia
645 prevention by stroke prevention. *Alzheimer's Dement*. 2019;15(7):865-869.
646 doi:10.1016/j.jalz.2019.06.003
- 647 21. Hachinski V, Einhäupl K, Ganten D, et al. Preventing dementia by preventing stroke: The
648 Berlin Manifesto. *Alzheimer's Dement*. 2019;15(7):961-984. doi:10.1016/j.jalz.2019.06.001
- 649 22. Wang N, Allali G, Kesavadas C, et al. Cerebral Small Vessel Disease and Motoric
650 Cognitive Risk Syndrome: Results from the Kerala-Einstein Study. *J Alzheimer's Dis*.
651 2016;50(3):699-707. doi:10.3233/JAD-150523
- 652 23. Nadkarni NK, Perera S, Snitz BE, et al. Association of brain amyloid- β with slowgait in
653 elderly individuals without dementia influence of cognition and apolipoprotein e ϵ 4
654 genotype. *JAMA Neurol*. 2017;74(1):82-90. doi:10.1001/jamaneurol.2016.3474
- 655 24. Cohen JA, Verghese J, Zwerling JL. Cognition and gait in older people. *Maturitas*.
656 2016;93:73-77. doi:10.1016/j.maturitas.2016.05.005
- 657 25. Beauchet O, Sekhon H, Barden J, et al. Association of motoric cognitive risk syndrome
658 with cardiovascular disease and risk factors: Results from an original study and meta-
659 analysis. *J Alzheimer's Dis*. 2018;64(3):875-887. doi:10.3233/JAD-180203
- 660 26. Sathyan S, Wang T, Ayers E, Verghese J. Genetic basis of motoric cognitive risk
661 syndrome in the Health and Retirement Study. *Neurology*. 2019;92(13):E1427-E1434.
662 doi:10.1212/WNL.00000000000007141
- 663 27. Donini LM, Savina C, Gennaro E, et al. A systematic review of the literature concerning
664 the relationship between obesity and mortality in the elderly. *J Nutr Heal aging* 2012 161.
665 2011;16(1):89-98. doi:10.1007/S12603-011-0073-X
- 666 28. G R Neri S, S Oliveira J, B Dario A, M Lima R, Tiedemann A. Does Obesity Increase the
667 Risk and Severity of Falls in People Aged 60 Years and Older? A Systematic Review and
668 Meta-analysis of Observational Studies. *Journals Gerontol Ser A*. 2020;75(5):952-960.
669 doi:10.1093/GERONA/GLZ272
- 670 29. Sathyan S, Barzilai N, Atzmon G, Milman S, Ayers E, Verghese J. Association of anti-
671 inflammatory cytokine IL10 polymorphisms with motoric cognitive risk syndrome in an
672 Ashkenazi Jewish population. *Neurobiol Aging*. 2017;58:238.e1-238.e8.
673 doi:10.1016/j.neurobiolaging.2017.06.006
- 674 30. P C, A L, C C-D, et al. IL-10 alters immunoproteostasis in APP mice, increasing plaque
675 burden and worsening cognitive behavior. *Neuron*. 2015;85(3):519-533.
676 doi:10.1016/J.NEURON.2014.11.020
- 677 31. Verghese J, Holtzer R, Wang C, Katz MJ, Barzilai N, Lipton RB. Role of APOE genotype
678 in gait decline and disability in aging. *Journals Gerontol - Ser A Biol Sci Med Sci*.
679 2013;68(11):1395-1401. doi:10.1093/gerona/glt115
- 680 32. Wirths O, Bayer TA. Motor impairment in Alzheimer's disease and transgenic
681 Alzheimer's disease mouse models. *Authors J Compil #*. 2008;7:1-5. doi:10.1111/j.1601-
682 183X.2007.00373.x
- 683 33. Ayers E, Verghese J. Diagnosing motoric cognitive risk syndrome to predict progression
684 to dementia. *Neurodegener Dis Manag*. 2014;4(5):339-342. doi:10.2217/nmt.14.39
- 685 34. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated

- guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. doi:10.1186/s13643-021-01626-4
35. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of Observational Studies in Epidemiology A Proposal for Reporting. *JAMA*. 2000;15:2008-2012. doi:10.1001/jama.283.15.2008
36. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. *J Clin Epidemiol*. 2016;75:40-46. doi:10.1016/j.jclinepi.2016.01.021
37. Riley RD, Moons KGM, Snell KIE, et al. A guide to systematic review and meta-analysis of prognostic factor studies. *BMJ*. 2019;364. doi:10.1136/bmj.k4597
38. Covidence systematic review software. Accessed August 24, 2021. <https://support.covidence.org/help/how-can-i-cite-covidence>
39. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. *Trials*. 2007;8. doi:10.1186/1745-6215-8-16
40. Higgins J, Thomas J, Chandler J, et al. *Cochrane Handbook for Systematic Reviews of Interventions | Cochrane Training*. Vol 6.2. 6.2.; 2021. Accessed April 15, 2021. <https://training.cochrane.org/handbook/current>
41. Harrer M, Cuijpers P, Furukawa TA, Ebert DD. *Doing Meta-Analysis in R: A Hands-on Guide*.; 2019. doi:10.5281/zenodo.2551803
42. Viechtbauer W, Wolfgang V. Conducting meta-analyses in R with the metafor package. *J Stat Software*. 2010;36(3):1-48. <http://www.jstatsoft.org/>
43. Huguet A, Hayden JA, Stinson J, et al. Judging the quality of evidence in reviews of prognostic factor research: Adapting the GRADE framework. *Syst Rev*. 2013;2(1). doi:10.1186/2046-4053-2-71
44. Beauchet O, Sekhon H, Launay CP, Gaudreau P, Morais JAJA, Allali G. Relationship between motoric cognitive risk syndrome, cardiovascular risk factors and diseases, and incident cognitive impairment: Results from the “NuAge” study. *Maturitas*. 2020;138(May):51-57. doi:10.1016/j.maturitas.2020.05.007
45. Beauchet O, Sekhon H, Cooper-Brown L, et al. Motoric cognitive risk syndrome and incident dementia in older adults from the Québec NuAge cohort. *Age Ageing*. Published online November 17, 2020. doi:10.1093/ageing/afaa235
46. Kumai K, Meguro K, Kasai M, et al. Neuroepidemiologic and Neurobehavioral Characteristics of Motoric Cognitive Risk Syndrome in an Old-Old Population: The Kurihara Project. *Dement Geriatr Cogn Dis Extra*. 2016;6(2):176-182. doi:10.1159/000445539
47. Liu Y, Wei K, Cao X, et al. Development and Validation of a Nomogram Based on Motoric Cognitive Risk Syndrome for Cognitive Impairment. *Front Aging Neurosci*. 2021;13:618833. doi:10.3389/fnagi.2021.618833
48. Chhetri JK, Zheng Z, Xu X, Ma C, Chan P. The prevalence and incidence of frailty in Pre-diabetic and diabetic community-dwelling older population: Results from Beijing longitudinal study of aging II (BLSA-II). *BMC Geriatr*. 2017;17(1). doi:10.1186/s12877-017-0439-y
49. Study Quality Assessment Tools | NHLBI, NIH. Accessed April 15, 2021. <https://www.nlm.nih.gov/health-topics/study-quality-assessment-tools>
50. Vandenbroucke JP, Von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. *PLoS Med*. 2007;4(10):1628-1654. doi:10.1371/journal.pmed.0040297
51. Wolff RF, Moons KGM, Riley RD, et al. PROBAST: A tool to assess the risk of bias and applicability of prediction model studies. *Ann Intern Med*. 2019;170(1):51-58. doi:10.7326/M18-1376

- 737 52. McGuinness L. robvis: An R package and web application for visualising risk-of-bias
738 assessments. Published online 2019.
739

740 Table 1 – Characteristics of studies
741 Table 2 – GRADE assessment of certainty in results
742 Table 3 – Excluded studies
743





























Table 1 Characteristics and results of the studies included in the meta-analysis (further details in supplementary table 3)

MCR as a predictor of Dementia				
Study	Size	MCR prevalence %	Age mean years	Result (95% CI)
Doi et al. (2017)	4235	6.3	72	2.49 (1.52, 4.1) p<0.001
Verghese et al. (2013)	767	6.8	79.9	2.72 (1.24, 5.97) p=0.013
Verghese et al. (2014a1i)	1280	13	79.9	2.1 (1.43, 2.09)
Verghese et al. (2014a2i)	1013	13	75.1	1.98 (1.44, 2.74)
Verghese et al. (2014a3i)	1562	9	72.3	1.79 (1.31, 2.44)
Beauchet et al. (2020c)	1098	4.2	73.8	5.18 (2.43, 11.03) p≤0.001
MCR as a predictor of Cognitive Impairment				
Study	Size	MCR prevalence %	Age mean years	Result (95% CI)
Aguilar-Navarro et al. (2019)	726	14.3	69.8	2.46 (1.25, 4.84) p=0.009
Verghese et al. (2014a1)	1280	13	79.9	1.49 (1.08, 2.07) p=0.015
Verghese et al. (2014a2)	1013	13	75.1	1.9 (1.44, 2.51) p=0.001
Verghese et al. (2014a3)	1562	9	72.3	1.48 (1.16, 1.88) p=0.002
Verghese et al. (2014a4)	700	8	74.1	2.74 (1.54, 4.86) p=0.001
Liu et al. (2021)	1177	6.7	65	1.95 (1.21, 2.82)
MCR as a predictor of Falls				
Study	Size	MCR prevalence %	Age mean years	Result (95% CI)
Callisaya et al. (2016a1)	509	11	75	1.06 (0.74, 1.52)
Callisaya et al. (2016a2)	817	12.1	79.7	1.18 (0.93, 1.49)
Callisaya et al. (2016a3)	3640	6.7	74.4	1.37 (1.18, 1.58)
Callisaya et al. (2016a4)	832	6.9	73.5	1.78 (1.23, 2.55)
Callisaya et al.	406	1.7	72	2.15 (1.57, 2.94)

(2016a5)				
Beauchet et al. (2019b)	5958	9.9	80.2	1.18 (1.02, 1.36)
Lord et al. (2020a1)	302	1.9	84.6	1.67 (0.86, 3.23)
Lord et al. (2020a2)	176	4.3	82.6	0.46 (0.07, 2.83)
MCR as a predictor of Mortality				
Study	Size	MCR prevalence %	Age mean years	Result (95% CI)
Ayers and Verghese (2016a1)	4686	8	74.7	1.87 (1.54, 2.28)
Ayers and Verghese (2016a2)	6795	6.4	77.3	1.62 (1.21, 2.16)
Ayers and Verghese (2016a3)	4559	7	81.7	1.5 (1.04, 2.16)
Beauchet et al. (2019a)	3778	10.1	80.5	1.09 (0.89, 1.34) p=0.401

Note: Results are adjusted hazard ratios except for those cohorts with falls as the outcome, which are adjusted relative risk. MCR (Motoric Cognitive Risk); CI (Confidence Interval)

748 Table 2: GRADE assessment of certainty in the body of evidence for MCR as a predictor of each health outcome

Participants and setting: Longitudinal cohort studies of older adults in community settings									
Exposure: MCR or both of its components, objective slow gait speed and subjective cognitive complaint									
Comparator: a non-MCR group									
Outcomes & Effect size (95%CI)	No.	Phase	ROB	Inconsist.	Imprecis.	Indirect.	Pub. bias	Effect size	GRADE certainty of evidence
Dementia aHR 2.12 (1.85-2.42)	9955								⊕⊕⊕⊕ Low
Cognitive Impairment aHR 1.76 (1.49-2.08)	6458								⊕⊕⊕⊕ Low
Falls aRR 1.38 (1.15-1.66)	12640								⊕⊕⊕⊕ Low
Mortality aHR 1.49 (1.16-1.91)	19818								⊕⊕⊕⊕ Low

749 Note: aHR (adjusted hazard ratio); aRR (adjusted relative risk); No. (Number of participants in pooled meta-analysis for each outcome); Phase
750 (Phase of Investigation); ROB (Risk of Bias); Inconsist. (Inconsistency); Imprecis. (Imprecision); Indirect. (Indirectness); Pub. Bias (Publication Bias)


751 High certainty: We are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: We are moderately confident in
752 the effect estimate – the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty:
753 Our confidence in the effect estimate is limited – the true effect may be substantially different from the estimate of the effect.

754
755


Table 3 Characteristics of studies excluded from meta-analysis due to incompatible effect measures or lack of similar studies

Incompatible effect measures										
Study	Outcome	Country	Cohort	Size	Female %	MCR prevalence %	Age mean years	Time years	Result (95% CI)	ROB
Beauchet et al. (2020a)	Dementia	France	EPIDOS	651	100	13.5*	79.5	7	aOR 2.07 (1.06-4.02) p=0.033	Mod.
Kumai et al. (2016)	Dementia	Japan	Kurihara	516	61	11.1	79.8	4	aOR 1.38 (NR)	High
Allali et al. (2016)	Cognitive Impairment	USA	CCMA	314	32	8	79.4	2	aOR 3.59 (1.30-10.10) p=0.016	Mod.
Beauchet et al. (2020b)	Cognitive Impairment	Canada	NuAGE	1113	51.9	4.2	73.8	3	aOR 5.16 (CI 2.20-12.08) p≤0.001	Mod.
Lack of similar studies										
Study	Outcome	Country	Cohort	Size	Female %	MCR prevalence %	Age mean years	Time years	Result (95% CI) p-value	ROB
Doi 2017	Disability	Japan	OSHPE	4235	50	6.3	72	2.5	aHR 2.25 (1.39-3.67) p=0.001	Low
Beauchet 2019b	Falls recurrence (>=2)	France	EPIDOS	5958	100	9.9	80.2	4	aHR 1.46 (1.04-2.05) p=0.030	Mod.
Beauchet 2019b	Post-fall hip fractures	France	EPIDOS	5958	100	9.9	80.2	4	aHR 2.54 (1.78-3.63) p≤0.001	Mod.

Note: *MCR prevalence is different to that reported in the study abstract as we calculated 88 / 651 had MCR (47 slowed walking, 41 slowed walking and slowed five-times sit-to-stand).
MCR (Motoric Cognitive Risk); CI (Confidence Interval); ROB (Risk of Bias); aOR (adjusted odds ratio); aHR (adjusted hazards ratio); HR (hazard ratio); NR (not reported); CCMA (Central Control of Mobility in Aging); OSHPE (Obu Study of Health Promotion for the Elderly); NuAGE (Quebec Longitudinal Study on Nutrition and Successful Aging); EPIDOS (Epidemiologie de l'Osteoporose);



From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71. For more information, visit: <http://www.prisma-statement.org/>



Risk of bias domains										
	D1	D2	D3	D4	D5	D6	D7	D8	D9	Overall
Aguilar-Navarro 2019	-	-	-	+	-	+	X	+	+	+
Ayers 2016	+	+	+	+	-	+	-	+	-	+
Beauchet 2019a	+	+	-	+	-	+	+	+	X	-
Beauchet 2019b	+	+	-	+	-	+	+	+	X	-
Beauchet 2020c	+	-	+	-	-	X	+	X	-	-
Callisaya 2016	+	+	+	+	-	+	+	+	+	+
Doi 2017	+	+	+	+	+	+	-	+	-	+
Liu 2021	-	+	-	+	+	X	+	+	-	-
Lord 2020	-	+	-	-	+	X	+	-	-	X
Vergheze 2013	+	+	+	+	-	+	+	+	+	+
Vergheze 2014	+	+	+	+	X	+	+	+	+	+

D1: Bias due to study focus
D2: Bias due to cohort
D3: Bias due to MCR measurement
D4: Bias due to outcome measurement
D5: Bias due to missing data
D6: Bias due to confounding
D7: Bias due to follow-up
D8: Bias due to results precision
D9: Bias due to generalisability

Judgement

X High
- Unclear
+ Low

Study	Cohort	Size	MCR & Cognitive Impairment	HR	95%-CI	Weight
-------	--------	------	----------------------------	----	--------	--------


Verghese et al. (2014a3)	H-EPESE	1562		1.48	[1.16; 1.88]	29.5%
Verghese et al. (2014a2)	ROS	1013		1.90	[1.44; 2.51]	24.6%
Verghese et al. (2014a1)	MAP	1280		1.49	[1.08; 2.06]	19.6%
Liu et al. (2021)	CHARLS	1177		1.95	[1.28; 2.98]	13.0%
Verghese et al. (2014a4)	InCHIANTI	700		2.74	[1.54; 4.87]	7.6%
Aguilar-Navarro et al. (2019)	MHAS	726		2.46	[1.25; 4.84]	5.7%

Random effect model total

Prediction interval

Heterogeneity: $I^2 = 24.9\%$, $\tau^2 = 0.0095$

$p = <0.0001$



Study	Cohort	Size	MCR and Dementia	HR	95%-CI	Weight
-------	--------	------	------------------	----	--------	--------


Verghese et al. (2014a1i)	MAP	1280		2.10	[1.74; 2.54]	50.3%
Verghese et al. (2014a3i)	H-EPESE	1562		1.79	[1.31; 2.44]	18.7%
Verghese et al. (2014a2i)	ROS	1013		1.98	[1.44; 2.73]	17.5%
Doi et al. (2017)	OS-HPE	4235		2.49	[1.52; 4.09]	7.4%
Beauchet et al. (2020c)	NuAGE	1098		5.18	[2.43; 11.04]	3.2%
Verghese et al. (2013)	EAS	767		2.72	[1.24; 5.97]	2.9%

Random effect model total

Prediction interval

Heterogeneity: $I^2 = 33.1\%$, $\tau^2 = <0.0001$

$p = <0.0001$



Study	Cohort	Size	MCR & Falls	RR	95%-CI	Weight
-------	--------	------	-------------	----	--------	--------


Beauchet et al. (2019b)	EPIDOS	5958		1.18	[1.02; 1.36]	19.8%
Callisaya et al. (2016a3)	HRS	3640		1.37	[1.18; 1.59]	19.7%
Callisaya et al. (2016a2)	EAS	817		1.18	[0.93; 1.49]	16.4%
Callisaya et al. (2016a5)	TASCOG	406		2.15	[1.57; 2.94]	13.6%
Callisaya et al. (2016a1)	LonGenity	509		1.06	[0.74; 1.52]	12.0%
Callisaya et al. (2016a4)	InCHIANTI	832		1.78	[1.24; 2.56]	11.9%
Lord et al. (2020a1)	LILACS Non-Maori	302		1.67	[0.86; 3.24]	5.7%
Lord et al. (2020a2)	LILACS Maori	176		0.46	[0.07; 2.92]	0.9%

Random effect model total

Prediction interval

Heterogeneity: $I^2 = 62.1\%$, $\tau^2 = 0.039$

$p = 0.0005$



Study	Cohort	Size	MCR & Mortality	HR	95%-CI	Weight
-------	--------	------	-----------------	----	--------	--------


Ayers and Verghese (2016a1)	HRS	4686		1.87	[1.54; 2.28]	28.4%
Beauchet et al. (2019a)	EPIDOS	3778		1.09	[0.89; 1.34]	28.0%
Ayers and Verghese (2016a2)	NHATS	6795		1.62	[1.21; 2.16]	23.6%
Ayers and Verghese (2016a3)	SHARE	4559		1.50	[1.04; 2.16]	19.9%

Random effect model total


Prediction interval

Heterogeneity: $I^2 = 79.2\%$, $\tau^2 = 0.0447$


$p = 0.002$




Cognitive Impairment



Dementia



Falls



Mortality

